Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARTISTEM for Talar Osteochondral Defect
NCT04310215Phase 3Completed
- Sponsor
- Hyundai Bioland
- Start
- Mar 2020
- Primary completion
- Jun 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of Cartistem in osteochondral lesion of the talus (OLT), sponsored by Hyundai Bioland. Started Mar 2020; status: completed.
02
Drugs
Cartistem
03
Conditions
osteochondral lesion of the talus (OLT)
Beyond the preview
Go deeper on NCT04310215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04310215.